Acute Myeloid Leukemia with Myelodysplastic Syndromes (AML-MDS), t(1;3)(p36;q21) subtype:

Please note: While we have created these reports with the goal of educating people with little scientific background, the reports contain some detailed information and we recommend that you view the Power Point Presentation on our web site home page before reading them.

This report is a 76 page meta-analysis completed for a female patient with Acute Myeloid Leukemia AML-MDS with a t(1;3)(p36;q21) subtype.

It is important to note that there are many different subtypes of AML-MDS so if this is not your subtype, then this report was not designed for the molecular processes specific to your cancer.

However, the report would still be of great benefit to you as it contains a substantial amount of information pertaining to all AML-MDS subtypes.

We will be adding reports of other AML-MDS subtypes as they are requested and we invite you to contact us to discuss the preparation of a report that looks specifically at your AML-MDS subtype.

In this report you will find detailed information on:

  • The causes of this disease; how it is diagnosed and characterized; statistics on various standard treatments and concerns we have regarding  certain standard approaches to treatment;
  • Detailed explanations on the disease causing molecular and genetic mechanisms that occur in the t(1;3)(p36;q21) subtype. A complete list of new drugs designed to target these molecular mechanisms;
  • Recent advances in treatment available through free clinical trials including optimized chemotherapy, non-chemotherapy gene-targeted approaches, and immunotherapy. We only include approaches that significantly improve life expectancy and survival time when compared to the standard treatments;
  • A customized diet plan designed to target the genes and molecular processes unique to the t(1;3)(p36;q21) subtype and the scientific studies showing the effectiveness of these supplements in treating AML-MDS. We also address how to improve the bioavailability and cancer fighting activity of these supplements and nutraceuticals;
  • Seven pages of peer reviewed references used in this report. This data alone would cost substantial amount if you were to purchase these papers separately at a cost of $20-40 each.